CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.31B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.56: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.31BUSDvs all stocks (USD)
Revenue (TTM)
42.69MEURvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.32xvs all stocks
52-Week Change
63.93%vs all stocks
Market Capitalization
1.31BUSDvs all stocks (USD)
Enterprise Value
979.48MUSDvs all stocks (USD)
Forward P/E
-4.94xvs Biotechnology peers
Price to Sales (TTM)
34.45xvs Biotechnology peers
Price to Book (MRQ)
2.47xvs Biotechnology peers
Enterprise to Revenue
22.95xvs Biotechnology peers
Enterprise to EBITDA
-4.20xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-867.89%vs Biotechnology peers
Return on Assets (TTM)
-22.44%vs Biotechnology peers
Return on Equity (TTM)
-43.21%vs Biotechnology peers
Revenue (TTM)
42.69MEURvs all stocks (USD)
Revenue per Share (TTM)
0.2970EURUpdated Jul 19, 2026Quarterly Revenue Growth
-59.00%vs Biotechnology peers
Gross Profit (TTM)
-187.49MEURvs all stocks (USD)
EBITDA (TTM)
-233.40MEURvs all stocks (USD)
Net Income (TTM)
-245.39MEURvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-59.04%vs Biotechnology peers
Operating Cash Flow (TTM)
-211.12MEURvs all stocks (USD)
Levered Free Cash Flow (TTM)
-126.87MEURvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
48.27MEURFY2025 · Dec 31, 2025Operating Income
-182.02MEUR-210.06M · vs all stocks (USD)
Pre-tax Income
-198.44MEURFY2025 · Dec 31, 2025Income Tax Expense
-1.99MEURFY2025 · Dec 31, 2025Net Income
-196.45MEURFY2025 · Dec 31, 2025EBIT
-197.49MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-152.44MEURFY2025 · Dec 31, 2025Research & Development
183.83MEURFY2025 · Dec 31, 2025Selling, General & Administrative
51.18MEURFY2025 · Dec 31, 2025Other Operating Expenses
-4.73MEURFY2025 · Dec 31, 2025Non-operating Interest Income
17.18MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
946.00KEURFY2025 · Dec 31, 2025Net Income from Continuing Operations
-196.45MEURFY2025 · Dec 31, 2025Operating Cash Flow
-231.22MEURFY2025 · Dec 31, 2025Free Cash Flow
-237.78MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
345.92MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-196.45MEURFY2025 · Dec 31, 2025Depreciation & Amortization
12.40MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.99MEURFY2025 · Dec 31, 2025Stock-based Compensation
15.02MEURFY2025 · Dec 31, 2025Other Non-cash Items
-16.23MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-242.00KEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-43.72MEURFY2025 · Dec 31, 2025Capital Expenditures
-6.56MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-247.00KEURFY2025 · Dec 31, 2025Purchase of Investments
-338.27MEURFY2025 · Dec 31, 2025Sale of Investments
549.86MEURFY2025 · Dec 31, 2025Net Investing Cash Flow
205.03MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-2.96MEURFY2025 · Dec 31, 2025Other Financing Charges
-7.00MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
97.35MEURFY2025 · Dec 31, 2025Shares Outstanding
136.67MSharesUpdated Jul 19, 2026Float Shares
69.59MSharesUpdated Jul 19, 2026Shares Short
5.41MSharesUpdated Jul 19, 2026Short Ratio
10.25daysvs all stocks
Short % of Shares Outstanding
5.73%vs all stocks
% Held by Insiders
17.58%vs all stocks
% Held by Institutions
79.47%vs all stocks
Total Cash (MRQ)
519.12MEURvs all stocks (USD)
Total Cash per Share (MRQ)
3.32EURUpdated Jul 19, 2026Total Debt (MRQ)
17.26MEURvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0331xvs Biotechnology peers
Current Ratio (MRQ)
8.78xvs Biotechnology peers
Book Value per Share (MRQ)
3.81EURUpdated Jul 19, 2026Total Assets
562.34MEUR648.97M · vs all stocks (USD)
Total Current Assets
504.01MEURFY2025 · Dec 31, 2025Total Liabilities
78.24MEURFY2025 · Dec 31, 2025Total Non-current Assets
58.33MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
35.23MEURFY2025 · Dec 31, 2025Total Current Liabilities
43.01MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
345.92MEURFY2025 · Dec 31, 2025Other Short-term Investments
123.42MEURFY2025 · Dec 31, 2025Accounts Receivable
6.10MEURFY2025 · Dec 31, 2025Accounts Payable
340.00KEURFY2025 · Dec 31, 2025Short-term Debt
2.76MEURFY2025 · Dec 31, 2025Deferred Revenue
15.82MEURFY2025 · Dec 31, 2025Other Current Liabilities
1.55MEURFY2025 · Dec 31, 2025Long-term Debt
12.88MEURFY2025 · Dec 31, 2025Common Stock (Book)
1.34MEURFY2025 · Dec 31, 2025Retained Earnings
-785.99MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
484.10MEUR558.68M · vs all stocks (USD)
52-Week Low
5.05USDUpdated Jul 19, 202652-Week High
12.41USDUpdated Jul 19, 202652-Week Change
63.93%vs all stocks
Beta
1.32xvs all stocks
50-Day MA
10.27USDUpdated Jul 19, 2026200-Day MA
10.10USDUpdated Jul 19, 2026Avg 10-Day Volume
386.33KSharesUpdated Jul 19, 2026Avg 30-Day Volume
415.31KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.95EURUpdated Jul 19, 2026Other Income / Expense
-32.65MEURFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 34.45Revenue Growth YoY: -0.59
Financial Health
Altman Z-Score 6.56: safe zoneNotable
Altman Z-Score: 6.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.31B, above the global median of $1.15BNotable
Market cap (USD): 1,310,695,613Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule